Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

Figure 5

VEGF-activated blood vessels are reduced after CT-322 treatment. Immunohistochemistry using Gv39M, an antibody recognizing VEGF-activated blood vessels, and MECA-32 was performed on frozen sections of MiaPaCa-2 tumors from animals treated with control or CT-322. The percentage of MECA-32-positive blood vessels that were stained by Gv39M is displayed. Representative images of co-localization of MECA-32 (green) and Gv39M (red) is shown, magnification 200×. This represents two tumors per group, 8–10 high power fields, p < 0.05.

Back to article page
\